Objective: The purpose of this study was to evaluate MRI findings of ovarian endometrioid carcinoma (OEC) as a predictor of histological grade.
Materials And Methods: This study included 60 patients with histopathologically confirmed OEC (20, 30, and 10 with grades 1, 2, and 3, respectively). Clinical and MRI results were retrospectively reviewed. We compared the following parameters between the three grades: age, tumor markers, presence of uterine corpus cancer, bilaterality, configuration, peritoneal dissemination, abnormal ascites, signal intensities of cystic and solid components, tumor size, and apparent diffusion coefficient (ADC) values of solid components.
Results: T1-hyperintense cysts were more common in grade 1 than in grades 2-3 OEC (80% vs. 60%, vs. 40%, p < 0.05). The signal intensity ratio between the cystic components with the largest solid component and muscle (1.49 vs. 1.08 vs. 0.98, p < 0.05) was higher in grade 1 than in grades 2-3 OEC. Necrosis within solid components was less common in grade 1 than in grades 2-3 OEC (31% vs. 68% vs. 88%, p < 0.05), and the ADC values of solid components were higher in grade 1 than in grades 2-3 OEC (1.10 vs. 0.99 vs. 0.79 × 10 mm2/sec, p < 0.05). There were no significant differences in other factors.
Conclusion: On T1-weighted images, grade 1 OEC showed a higher signal intensity in the cystic components than grades 2-3 OEC. Necrosis and lower ADC values were more frequently observed in grades 2-3 than in grade 1 OEC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11604-024-01727-9 | DOI Listing |
Jpn J Radiol
December 2024
Department of Radiology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Objective: The purpose of this study was to evaluate MRI findings of ovarian endometrioid carcinoma (OEC) as a predictor of histological grade.
Materials And Methods: This study included 60 patients with histopathologically confirmed OEC (20, 30, and 10 with grades 1, 2, and 3, respectively). Clinical and MRI results were retrospectively reviewed.
EClinicalMedicine
January 2025
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric and Gynaecological Diseases, State Key Laboratory of Common Mechanism Research for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Ovarian cancer (OC) is a heterogeneous malignancy with multiple histological subtypes, showing global variability in incidence. Temporal changes in diagnostic criteria and risk factors might influence the incidence and distribution of OC and its subtypes.
Methods: This study analyzed incidence patterns (2013-2017) and trends (1988-1992 to 2013-2017) of OC and its subtypes across 65 and 40 countries, respectively.
Front Oncol
December 2024
Department of Gynaecologic Oncology, Center for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam University Medical Centres, Amsterdam, Netherlands.
Cancer Sci
December 2024
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ovarian carcinosarcoma (OCS) is a rare and aggressive tumor, and the development of its sarcomatous component is believed to be due to epithelial-mesenchymal transition (EMT). The SWIch/sucrose nonfermentable chromatin remodeling factor (CRF) is closely related to EMT; however, the relationship between CRF and EMT in OCS remains unclear. In this study, we analyzed the protein expression of CRFs, including ARID1A and SMARCA4, and their downstream mRNA expression in 28 OCS cases, two fallopian tube CS cases, and one peritoneal CS case.
View Article and Find Full Text PDFEur J Cancer
December 2024
Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Montpellier, France; Société Française de Médecine Prédictive et Personnalisée (SFMPP), Montpellier, France; Center for Ecological and Evolutionary Cancer Research (CREEC), Montpellier University, Montpellier, France. Electronic address:
Background: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!